Anaplastic large cell lymphoma (ALCL) limited to the skin is a distinct disease that is designated primary cutaneous ALCL (pcALCL). It has an indolent course with a significantly better prognosis compared to systemic ALCL (sALCL). Anaplastic lymphoma kinase (ALK) expression in lesions of cutaneous ALCL is classically considered to be a marker for skin involvement by sALCL. However, recent reports of patients with ALKpositive pcALCL challenge this concept and raise prognostic and therapeutic dilemmas. Herein, we report a case of ALK-positive pcALCL in a 45-year-old woman who was treated with local radiotherapy. We review previously reported cases in the literature to better characterize this rare variant. Overall, the rates of cutaneous recurrence, systemic dissemination, and disease-related mortality in ALK-positive pcALCL do not differ from those previously reported in pcALCL. ALK-positive pcALCL is diagnosed at younger age and has a better disease course in children compared to adults with lower incidences of skin recurrence and progression to systemic disease. We conclude that ALK-positivity in cutaneous ALCL does not necessarily imply systemic disease. ALK-positive pcALCL has an excellent prognosis and should be treated by excision and/or radiotherapy. However, patients must remain under close long-term follow-up as recurrence and progression to systemic disease may occur.
Introduction
Anaplastic large cell lymphoma (ALCL) is a CD30 + lymphoproliferative disorder that has two distinct forms with different disease courses: primary cutaneous ALCL (pcALCL) which has an excellent prognosis, and systemic ALCL (sALCL), a potentially aggressive lymphoma that primarily involves the lymph nodes and carries a less favorable course. sALCL is further divided into ALK-positive and ALK-negative subtypes, depending on the expression of the anaplastic lymphoma kinase (ALK) fusion protein. pcALCL is generally found to be ALK-negative, and ALK expression in skin lesions of ALCL evokes high suspicion for secondary skin involvement by sALCL. 1 Recently, ALKpositive pcALCL has been reported in both children and adults [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] with heterogenous courses described.
Case report
A 45-year-old woman presented to our multidisciplinary cutaneous lymphoma clinic with a 1-month history of a rapidly growing ulcerated nodule on her left abdomen. The patient was in otherwise good health without any significant past medical history. Complete review of systems was negative. Physical examination revealed a round 3-cm-in-diameter ulcerated red nodule with surrounding erythema (Fig. 1a, b) . No palpable lymphadenopathy was identified. Histopathological evaluation of lesional biopsies revealed dense dermal infiltrate of large atypical lymphocytes, positive for CD30, ALK-1, and TIA (Fig. 1c) .
Complete staging was performed to assess systemic disease.
Laboratory tests were unremarkable. Positron emission tomog- The patient was diagnosed with ALK-positive pcALCL and was treated by local radiation to her left abdominal skin with a complete response. A follow-up PET-CT performed 3.5 months after the initial imaging study revealed resolution of the hypermetabolic lymphadenopathy and the cutaneous mass, and no bone marrow FDG uptake was seen.
Discussion
PcALCL is generally conceptualized as part of the cutaneous CD30 + T-cell lymphoproliferative disorder spectrum. It is most commonly diagnosed in the sixth decade; however, it can also occur in childhood or adolescence. The majority of cases present with a rapidly growing solitary ulcerated nodule that can undergo partial or complete spontaneous regression. Overall, pcALCL carries a very favorable prognosis with a 5-year overall survival (OS) of 90%. 19 Cutaneous recurrences are not uncommon and occur in up to 40% of treated patients; however, progression to systemic disease is rare, affecting only 12-16%. 1, 20, 21 Overexpression of the ALK fusion protein has been postulated to have a role in the malignant transformation of sALCL. 22 In sALCL, ALK expression is found mainly in pediatric and young age groups 19 and is of prognostic significance as ALK-positive sALCL has a 5-year OS of 70% compared to an OS of 49% in ALK-negative sALCL. 19 ALK expression can also aid in therapeutic decision making: Crizotinib is an ALK tyrosine kinase inhibitor that can be used as treatment in ALK-positive sALCL. 23 Following the diagnosis of ALK-positive pcALCL in the presented case, and in a pediatric patient that had been recently reported by our institution, 8 The median age at diagnosis was 23.5 years (range which is noticeably younger than that reported for pcALCL.
Overall, the disease course and prognosis in the ALK-positive pcALCL cases reflected the literature on pcALCL 20, 21 ; 15.8% presented with more than one lesion, skin recurrence occurred in 27.8%, and extracutaneous dissemination developed in 16.7%. Two patients (10%) expired due to systemic disease.
Differences in disease course could be appreciated between pediatric and adult patients with ALK-positive pcALCL. None of the pediatric patients who had complete staging at diagnosis recurred or progressed to systemic disease, whether treated with excision/radiation (six cases) or with systemic chemotherapy (two cases). A single pediatric case did progress (11%) and expired due to disease; however, he had no staging workup done 14 . Among the adult cases, the rates of cutaneous recurrence and progression to systemic disease were 55.6% and 22.2%, respectively, and one adult died due to disease (11%). 
Recommendations and conclusions
Complete staging is mandatory in all pcALCL cases, and lym- 
